MGMT and glioblastoma: Among these, Anlotinib showed promising outcomes in terms of efficacy and tolerance in a clinical trial of newly diagnosed cases of GBM with unmethylated O6-Methylguanine-DNA Methyltransferase (MGMT) promoter [51], Cabozantinib showed some activity in patients with recurrent GBM who were not treated with antiangiogenic therapies, but did not meet the statistical significance for success [52].